Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
22°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
450.97
+0.60 (+0.13%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Vertex Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
48
49
Next >
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?
Today 5:47 EST
Via
The Motley Fool
Got $500? 1 Biotech Stock to Buy and Hold Forever
November 22, 2024
Via
The Motley Fool
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
November 18, 2024
Via
Benzinga
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
November 18, 2024
Via
The Motley Fool
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
November 16, 2024
Via
The Motley Fool
Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity
November 13, 2024
Regulators are reviewing what could become a multi-billion-dollar drug.
Via
The Motley Fool
Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity
November 05, 2024
Via
Benzinga
Assessing Vertex Pharmaceuticals: Insights From 11 Financial Analysts
November 05, 2024
Via
Benzinga
Looking Into Vertex Pharmaceuticals's Recent Short Interest
October 21, 2024
Via
Benzinga
Biotech Stocks Are Rallying: What Is Your Playbook?
November 11, 2024
If you have been reading our posts you know that some of the big biotech winners have taken a hit after earnings : LLY, MRK and REGN. But ABBV, GILD, LLY, and VRTX remain among the top performers.
Via
Talk Markets
Five S&P 500 Stocks, All Elite IBD Giants, Near Buy Points
November 09, 2024
Meta just forged a new base. All five stocks are on the IBD Leaderboard list.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review
November 08, 2024
A Fed rate cut and a slew of big earnings reports filled out a busy week.
Via
Investor's Business Daily
Topics
Economy
Government
Exposures
Interest Rates
Political
2 Biotech Stocks You Can Buy Hand Over Fist This Month
November 08, 2024
Both stocks have made significant breakthroughs.
Via
The Motley Fool
Wall Street Rallies On Election Day, Palantir Skyrockets, Bitcoin Tops $70,000: What's Driving Markets Tuesday?
November 05, 2024
Wall Street rallied on Tuesday as improved investor sentiment aligned with millions of Americans casting their votes for the 47th president.
Via
Benzinga
5 Top Stocks to Buy in November
November 05, 2024
From blue chip dividend stocks to industry-leading growth stocks, there are plenty of bargains in today's market if you know where to look.
Via
The Motley Fool
My 2 Favorite Growth Stocks to Buy Hand Over Fist in November
November 05, 2024
The sky's the limit for these stocks.
Via
The Motley Fool
Vertex Pharmaceuticals (VRTX) Q3 2024 Earnings Call Transcript
November 04, 2024
VRTX earnings call for the period ending September 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms
November 04, 2024
Vertex Pharmaceuticals beat third-quarter expectations on Monday. The company also raised its sales outlook.
Via
Investor's Business Daily
Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required
November 04, 2024
A bit of earnings and election jitters roiled the market last week reordering the leaderboard in biopharma stocks.
Via
Talk Markets
Wall Street Struggles Ahead Of Election Day, Energy Sector Outperforms, Solar Stocks Rise: What's Driving Markets Monday?
November 04, 2024
The U.S. stock market struggled to gain momentum on Monday as investors remained cautious ahead of Election Day on Tuesday.
Via
Benzinga
Jim Cramer Says Vertex Doing 'Lord's Work': Can Q3 Earnings Outshine Bearish Charts?
November 04, 2024
VRTX to report Q3 earnings, expected EPS $4.14 and $2.72B in revenue. Cramer calls it a buy, analysts see 22% upside. Stock faces bearish trend.
Via
Benzinga
Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers
November 02, 2024
It won't be able to be profitable without hitting its targets for both of these figures.
Via
The Motley Fool
As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report
November 01, 2024
Amid the election, and a Fed rate vote, earnings season roars ahead.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Jim Cramer: This Financial Stock Is 'One Of The Most Consistent, Great Companies'
October 31, 2024
Mad Money's Jim Cramer recommends buying T. Rowe Price Group. "I think it's such a great company," he added.
Via
Benzinga
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 5 Years
October 28, 2024
Via
Benzinga
These 10 Stocks Were The Best S&P 500 Performers In 2017 When Trump Was President: Will History Repeat Itself?
October 28, 2024
A look back at the top 10 S&P 500 performing stocks in 2017 under Donald Trump's first year as president and what it could mean for his re-election efforts.
Via
Benzinga
Topics
Government
Stocks
Exposures
Political
US Equities
12 High-Growth Stocks That Could Deliver Parabolic Returns
October 28, 2024
These 12 innovative companies could deliver exponential returns over the next quarter century.
Via
The Motley Fool
The Smartest Growth Stock to Buy With $500 Right Now
October 25, 2024
This stock might not be available for under $500 for long.
Via
The Motley Fool
Vertex Pharmaceuticals Just Found Its Newest Blockbuster Drug. A $41 Billion Market Awaits
October 24, 2024
Its latest report of clinical data suggests it has a winner on its hands.
Via
The Motley Fool
Why We Buy Stocks
October 21, 2024
Is fear of missing out (FOMO) controlling your portfolio?
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
48
49
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.